Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
201-220 of 991 trials

Carotid Stenosis: Ficolin-2 and Inflammation Study

We are investigating how levels of ficolin-2 relate to inflammation in the carotid arteries and brain in patients who have had a stroke or transient ischemic attack. This research may help us understand the underlying causes of these conditions better.

Stroke or Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyInternal MedicineNeurology

Advanced Non-Small Cell Lung Cancer: THIO with Cemiplimab

We are studying the safety and effectiveness of a new treatment combining THIO and cemiplimab for people with advanced non-small cell lung cancer. This trial aims to find out if this combination works better than THIO alone for patients who have already been treated.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Chronic Lymphocytic Leukemia: Venetoclax and Obinutuzumab Study

We are assessing the effectiveness and safety of a combination treatment for adults with recurring chronic lymphocytic leukemia. This study aims to understand how well the treatment works and what side effects may occur.

Recurrent Chronic Lymphocytic Leukemia1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyOncology

Choroidal Melanoma: Belzupacap Sarotalocan Treatment

We are studying a new treatment for people with primary indeterminate lesions or small choroidal melanoma. The goal is to see if it is more effective and safe compared to a placebo.

Choroidal Melanoma>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOncologyOphthalmology

Cholestatic Pruritus: Volixibat Study

We are testing a new drug, volixibat, for patients with itching caused by primary biliary cholangitis. The study aims to see if it can reduce itching and improve quality of life compared to a placebo.

Primary Biliary Cholangitis6-12 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInternal Medicine

Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia

We are studying a new treatment for children with relapsed or refractory Acute Lymphoblastic Leukemia to see how well it works and how safe it is. This trial includes both single-agent and combination therapy approaches.

Recurrent Pediatric Acute Lymphoblastic LeukemiaSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Atopic Dermatitis in Children: Upadacitinib vs. Dupilumab

We are studying whether upadacitinib is as safe and effective as dupilumab for children aged 2 to under 12 with moderate to severe atopic dermatitis. This trial aims to find better treatment options for young patients.

Atopic Dermatitis>2 yearsConfirmation phase (III)>20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteAllergologyDermatologyPediatrics

Guselkumab for Active Psoriatic Arthritis Axial Disease

We are studying whether guselkumab can help reduce symptoms in people with active psoriatic arthritis axial disease who have not been treated before. Participants will receive either the medication or a placebo.

Psoriatic Arthritis1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Myelofibrosis: Navtemadlin with Ruxolitinib

We are studying whether adding navtemadlin to ruxolitinib helps patients with myelofibrosis who aren't responding well to their current treatment. The trial looks at changes in spleen size and symptoms, along with safety and survival.

MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematologyOncology

Guselkumab for Pediatric Crohn’s Disease

We are studying the safety and effectiveness of guselkumab in children with moderately to severely active Crohn’s disease. This trial aims to see how well the treatment works after initial positive responses.

Crohn's Disease1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Chronic Pouchitis in Children: Vedolizumab IV Study

We are testing the intravenous medication vedolizumab in children with active chronic pouchitis to see if it helps them achieve remission. The study will also look at how well the treatment is tolerated and its overall effectiveness.

Pouchitis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Cystic Fibrosis: VX-522 Treatment Study

We are testing a new medication, VX-522, for adults with cystic fibrosis who do not respond to current treatments. The study will help us understand its safety and effectiveness compared to existing therapies.

Cystic Fibrosis6-12 monthsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPulmonology

Epcoritamab for Relapsed/Refractory Chronic Lymphocytic Leukemia

We are studying a new treatment called epcoritamab for patients with relapsed or refractory chronic lymphocytic leukemia and Richter's syndrome. The goal is to assess its safety and effectiveness, both alone and with other medications.

Chronic Lymphocytic Leukemia>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Heart Failure: JTT-861 Medication Study

We are evaluating a new medication, JTT-861, for individuals with heart failure with reduced ejection fraction. The study aims to see if it is safe and effective in improving heart function.

Heart Failure with Reduced Ejection FractionEfficacy phase (II)Investigational MedicinesCost ReimbursementCardiologyInternal Medicine

Advanced Solid Tumors: GRWD5769 Treatment Study

We are testing the safety and effectiveness of GRWD5769 alone and with cemiplimab in patients with advanced solid tumors. This study aims to find out how well these treatments work and their tolerability.

Malignant Solid Tumor1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Cutaneous Lupus Erythematosus: Litifilimab Injections

We are studying the long-term safety and effects of Litifilimab injections for adults with active cutaneous lupus erythematosus who have not responded to other treatments. This research aims to see if it can improve symptoms and overall quality of life.

Skin Lupus (Cutaneous Lupus Erythematosus)>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Bomedemstat vs Best Available Therapy for Essential Thrombocythemia

We are studying a new treatment for patients with essential thrombocythemia who haven't responded to hydroxyurea. The trial aims to see if bomedemstat is safer and more effective than current therapies.

Essential Thrombocythemia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematology

Chronic Kidney Disease in Children: Finerenone Study

We are studying how well finerenone works and its safety for children with chronic kidney disease and proteinuria. This trial will help us understand its effects when used with standard treatments.

ProteinuriaChronic Kidney Disease6-12 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Chronic Kidney Disease: Finerenone Safety Study

We are studying the long-term safety of finerenone for children and young adults with chronic kidney disease. This trial looks at its effects when used alongside standard treatments like ACE inhibitors or ARBs.

Chronic Kidney DiseaseProteinuria1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNephrologyPediatrics

Non-Small Cell Lung Cancer: V940 and Pembrolizumab Study

We are testing a new treatment combining V940 with pembrolizumab for patients with resected stage II to IIIB non-small cell lung cancer. The study aims to see if this combination improves survival and quality of life compared to a placebo.

Non-small Cell Lung Cancer>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementOncology